Preparing your results

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Fibroblast growth factor receptor 3 is a negative regulator of bone growth.

Cell | Mar 22, 1996

http://www.ncbi.nlm.nih.gov/pubmed/8601314

Endochondral ossification is a major mode of bone that occurs as chondrocytes undergo proliferation, hypertrophy, cell death, and osteoblastic replacement. We have identified a role for fibroblast growth factor receptor 3 (FGFR-3) in this process by disrupting the murine Fgfr-3 gene to produce severe and progressive bone dysplasia with enhanced and prolonged endochondral bone growth. This growth is accompanied by expansion of proliferating and hypertrophic chondrocytes within the cartilaginous growth plate. Thus, FGFR-3 appears to regulate endochondral ossification by an essentially negative mechanism, limiting rather than promoting osteogenesis. In light of these mouse results, certain human disorders, such as achondroplasia, can be interpreted as gain-of-function mutations that activate the fundamentally negative growth control exerted by the FGFR-3 kinase.

Pubmed ID: 8601314 RIS Download

Mesh terms: Animals | Base Sequence | Blotting, Northern | Bone Development | Bone and Bones | Fibroblast Growth Factors | Gene Expression Regulation, Developmental | Heterozygote | In Situ Hybridization | Mice | Mice, Mutant Strains | Molecular Sequence Data | Mutation | Phenotype | Protein-Tyrosine Kinases | Receptor, Fibroblast Growth Factor, Type 3 | Receptors, Fibroblast Growth Factor | Spine | Stem Cells

Research resources used in this publication

None found

Research tools detected in this publication

None found

Data used in this publication

None found

Associated grants

  • Agency: NIDCD NIH HHS, Id: DC01393

Mouse Genome Informatics (Data, Gene Annotation)

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.